Live· 85 releases in the last 30 days
GLP-1 and obesity announcements, from the source.
Trial data, manufacturing capacity, supply constraints, pricing decisions and access programmes. The most-covered drug class in a decade, and most of what moves it is announced in a release first.
Latest on this wire
Releases are matched on the headline, deduplicated, and exclude securities-litigation solicitations. Each links to the publisher's original.
What to watch for
Supply and pricing releases outnumber the trial data and matter more commercially. A capacity announcement is a demand forecast the company is willing to put in writing.
Frequently asked questions
- Why is this separate from health?
- Because the search intent is. People looking for GLP-1 news are not browsing healthcare generally, and the volume justifies its own view.
- Does it cover compounders and telehealth?
- Yes, where they publish releases — that is a large part of the pricing and access story.
Monitoring obesity drugs on the wire
Why the wire beats the news
By the time a story is written, the release it came from has been public for hours — and the ones nobody wrote about are never seen at all. Most of what crosses this topic is the second kind: a regulator's notice, a mid-size company's filing, a ministry statement in a language the wires do not translate. That is where the stories nobody else has come from.
How current this page is
This page refreshes hourly and shows the twelve most recent matching releases. The live feed updates continuously and reaches the whole archive, and alerts fire the moment a new release matches.
You are seeing 12 of 85.
The other 73 crossed the wire in the last 30 days on this topic alone — most of them never reached a news site. A release is only useful before everyone else has it, and this page is a day behind by design.
Watch this topic live →Free to start. No card. Cancel in one click.